As of 2025-08-18, the Relative Valuation of Inhibikase Therapeutics Inc (IKT) is (5.06) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.75 USD, the upside of Inhibikase Therapeutics Inc based on Relative Valuation is -389.4%.
The range of the Relative Valuation is (3.69) - (6.83) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 14.1x | 10.8x |
| Forward P/E multiples | 5.7x - 13.9x | 9.8x |
| Fair Price | (3.69) - (6.83) | (5.06) |
| Upside | -310.7% - -490.5% | -389.4% |
| Date | P/E |
| 2025-08-15 | -3.56 |
| 2025-08-14 | -3.48 |
| 2025-08-13 | -3.48 |
| 2025-08-12 | -3.56 |
| 2025-08-11 | -3.07 |
| 2025-08-08 | -2.91 |
| 2025-08-07 | -3.15 |
| 2025-08-06 | -3.52 |
| 2025-08-05 | -3.66 |
| 2025-08-04 | -3.25 |
| 2025-08-01 | -3.09 |
| 2025-07-31 | -3.21 |
| 2025-07-30 | -3.36 |
| 2025-07-29 | -3.46 |
| 2025-07-28 | -3.60 |
| 2025-07-25 | -3.60 |
| 2025-07-24 | -3.76 |
| 2025-07-23 | -4.03 |
| 2025-07-22 | -3.93 |
| 2025-07-21 | -3.82 |
| 2025-07-18 | -3.74 |
| 2025-07-17 | -3.86 |
| 2025-07-16 | -3.78 |
| 2025-07-15 | -3.66 |
| 2025-07-14 | -3.95 |
| 2025-07-11 | -3.76 |
| 2025-07-10 | -4.07 |
| 2025-07-09 | -4.11 |
| 2025-07-08 | -4.09 |
| 2025-07-07 | -3.93 |
| 2025-07-03 | -3.84 |
| 2025-07-02 | -3.76 |
| 2025-07-01 | -3.97 |
| 2025-06-30 | -3.97 |
| 2025-06-27 | -3.30 |
| 2025-06-26 | -3.36 |
| 2025-06-25 | -3.40 |
| 2025-06-24 | -3.38 |
| 2025-06-23 | -3.38 |
| 2025-06-20 | -3.38 |
| 2025-06-18 | -3.46 |
| 2025-06-17 | -3.54 |
| 2025-06-16 | -3.95 |
| 2025-06-13 | -3.78 |
| 2025-06-12 | -3.88 |
| 2025-06-11 | -3.99 |
| 2025-06-10 | -4.08 |
| 2025-06-09 | -3.97 |
| 2025-06-06 | -3.99 |
| 2025-06-05 | -3.99 |